Mechanisms and Drug Intervention for Doxorubicin-Induced Cardiotoxicity Based on Mitochondrial Bioenergetics

被引:0
|
作者
Ling, Guanjing [1 ]
Wang, Xiaoping [1 ]
Tan, Nannan [1 ]
Cao, Jing [1 ]
Li, Weili [2 ]
Zhang, Yawen [1 ]
Jiang, Jinchi [1 ]
Sun, Qianbin [2 ]
Jiang, Yanyan [2 ]
Wang, Wei [1 ,3 ,4 ,5 ]
Wang, Yong [1 ,2 ,3 ,4 ]
机构
[1] School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing,100029, China
[2] School of Life Sciences, Beijing University of Chinese Medicine, Beijing,100029, China
[3] Beijing Key Laboratory of TCM Syndrome and Formula, Beijing,100029, China
[4] Key Laboratory of Beijing University of Chinese Medicine, Ministry of Education, Beijing,100029, China
[5] Guangzhou University of Chinese Medicine, Guangzhou,510006, China
关键词
Biochemistry - Diseases - Drug products - Mitochondria;
D O I
暂无
中图分类号
学科分类号
摘要
Doxorubicin (DOX) is an anthracycline chemotherapy drug, which is indispensable in antitumor therapy. However, its subsequent induction of cardiovascular disease (CVD) has become the primary cause of mortality in cancer survivors. Accumulating evidence has demonstrated that cardiac mitochondrial bioenergetics changes have become a significant marker for doxorubicin-induced cardiotoxicity (DIC). Here, we mainly summarize the related mechanisms of DOX-induced cardiac mitochondrial bioenergetics disorders reported in recent years, including mitochondrial substrate metabolism, the mitochondrial respiratory chain, myocardial ATP storage and utilization, and other mechanisms affecting mitochondrial bioenergetics. In addition, intervention for DOX-induced cardiac mitochondrial bioenergetics disorders using chemical drugs and traditional herbal medicine is also summarized, which will provide a comprehensive process to study and develop more appropriate therapeutic strategies for DIC. © 2022 Guanjing Ling et al.
引用
收藏
相关论文
共 50 条
  • [31] Doxorubicin-induced apoptosis: Implications in cardiotoxicity
    Kalyanaraman, B
    Joseph, J
    Kalivendi, S
    Wang, SW
    Konorev, E
    Kotamraju, S
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2002, 234 (01) : 119 - 124
  • [32] Neutrophils Contribute To Doxorubicin-induced Cardiotoxicity
    Bhagat, Anchit
    Kleinerman, Eugenie
    CIRCULATION RESEARCH, 2021, 129
  • [33] Oxidized phospholipids in Doxorubicin-induced cardiotoxicity
    Koleini, Navid
    Nickel, Barbara E.
    Edel, Andrea L.
    Fandrich, Robert R.
    Ravandi, Amir
    Kardami, Elissavet
    CHEMICO-BIOLOGICAL INTERACTIONS, 2019, 303 : 35 - 39
  • [34] Molecular mechanisms involved in doxorubicin-induced cardiotoxicity: A bibliometrics analysis by VOSviewer
    Yarmohammadi, Fatemeh
    Hayes, A. Wallace
    Karimi, Gholamreza
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (04) : 1971 - 1984
  • [35] Doxorubicin-induced cardiotoxicity and risk factors
    Belger, Carl
    Abrahams, Carmelita
    Imamdin, Aqeela
    Lecour, Sandrine
    IJC HEART & VASCULATURE, 2024, 50
  • [36] DEXRAZOXANE IN THE PREVENTION OF DOXORUBICIN-INDUCED CARDIOTOXICITY
    SEIFERT, CF
    NESSER, ME
    THOMPSON, DF
    ANNALS OF PHARMACOTHERAPY, 1994, 28 (09) : 1063 - 1072
  • [37] Myofilament changes in doxorubicin-induced cardiotoxicity
    Goncalves Rodrigues, P.
    Miranda-Silva, D.
    Barros, C.
    Handami, N.
    Linke, W.
    Falcao-Pires, I.
    Leite-Moreira, A. F.
    EUROPEAN HEART JOURNAL, 2014, 35 : 663 - 663
  • [38] Prevention of doxorubicin-induced cardiotoxicity by melatonin
    Eser Öz
    Deniz Erbaş
    H. Selçuk Sürücü
    Ersel Düzgün
    Molecular and Cellular Biochemistry, 2006, 282 : 31 - 37
  • [39] Amelioration of doxorubicin-induced cardiotoxicity by resveratrol
    Al-Harthi, Sameer E.
    Alarabi, Ohoud M.
    Ramadan, Wafaa S.
    Alaama, Mohamed N.
    Al-Kreathy, Huda M.
    Damanhouri, Zoheir A.
    Khan, Lateef M.
    Osman, Abdel-Moneim M.
    MOLECULAR MEDICINE REPORTS, 2014, 10 (03) : 1455 - 1460
  • [40] The role of autophagy in doxorubicin-induced cardiotoxicity
    Dirks-Naylor, Amie J.
    LIFE SCIENCES, 2013, 93 (24) : 913 - 916